InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-5.6%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by olivier Charmeil, Independent Director. Director active across 2 companies, notably GENOWAY. Aggregated, 6 disclosures have been recorded. Split: 3 buys · 0 sell. Total volume traded: €413k. Activity tracked since 4 May 2023. The latest transaction was filed on 20 August 2026 (Acquisition). Regulator: AMF. All data is openly available.
Companies and markets linked to olivier Charmeil
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
1,505.754 shares@ €77.56180.0001% mcap100.0% of flowParts de fonds d'épargne salarialeHors plateforme de négociationISIN QS00040862682026DD1135503
Canonical exit: 18 Nov 2026 (T+90)
55,000 shares0ActionHors plateforme de négociationISIN FR00001205782026DD1125509
7,000 shares0ActionHors plateforme de négociationISIN FR00001205782026DD1123406
21,145 shares0ActionHors plateforme de négociationISIN FR00001205782026DD1116396
Canonical exit: 23 Aug 2026 (T+90)
42,553 shares@ €2.3525.3% of flowActionHors plateforme de négociationISIN FR00040535102025DD1085526
80,000 shares@ €3.7074.7% of flowActionHors plateforme de négociationISIN FR00040535102023DD899714
Canonical exit: 2 Aug 2023 (T+90)
6 of 6 declarations
About olivier Charmeil
olivier Charmeil is Administrateur indépendant de genOway et Executive Vice President, General Medicines chez Sanofi. He has 5 filings in total, and across the 5 sampled recent filings, buy transactions total 396000 EUR and sell transactions total 0 EUR, with dates ranging from 2023-05-12 to 2026-07-07. The companies mentioned are SANOFI and GENOWAY, and the most frequent transaction nature is Mainlevée de nantissement.
